Not yet taking people in SwitzerlandNo phase
Follows adults with IgA nephropathy who take sparsentan in Switzerland
Observes how kidney disease changes in adults with IgA nephropathy receiving sparsentan.
Key facts
- Who runs it
- Waid City Hospital, Zurich
- Where
- Zurich, SwitzerlandSee the site
- Trial code
- Registry title
- Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
- Status
- Not yet recruiting
- People taking part
- 50 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Observational
- Treatments tested
- sparsentan
- Record updated
- 29 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with IgA nephropathy who are using sparsentan. It follows how their disease goes over time.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- IgA nephropathy
- Earlier treatment
- Must be using sparsentan
Main reasons for not taking part
- Younger than 18 years
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- IgA Nephropathy, Use of Sparsentan
Who cannot take part
- age < 18y
Where in Switzerland
- Stadtspital ZürichZurich, SwitzerlandContact: Andi SchleichNo longer taking part
About the trial
What the trial wants to find out
An observational study tracking the clinical course of patients with IgA nephropathy.
The group in the trial
- Patients with IgA Nephropathie and a therapy with Sparsentan
Treatment: sparsentan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
- Plain-language title
- Follows adults with IgA nephropathy who take sparsentan in SwitzerlandGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 29 April 2026